EN DE
Watch Hofseth Biocare ASA for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Hofseth Biocare ASA (HBC) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Hofseth Biocare ASA stock NOK 1.16, price NOK 1.12, upside +4.0%, quality 32 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Consumer Defensive NO · ISIN NO0010598683

HB Hofseth Biocare ASA logo Thin data Nov 10, 2026

Hofseth Biocare ASA

HBC · OL

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Fair value kr 1.16 · Fairly valued 
Mixed Growth (revenue 5y +29.9 %/yr in NOK) 
Negative equity (buybacks among others) 
Quality 32/100 
Falling price (downtrend) 
Loss-making · -56.4% net margin (TTM) 
Negative free cash flow 
Trails peers (1/7) 
Narrow moat 8/100 · thin data
Thin data 
Estimate
Watch Hofseth Biocare ASA for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 7.70 kr 1.09 Fair Value kr 1.16 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range kr 1.09 – kr 7.70 · fair‑value band kr 0.8700 – kr 1.45 · the kr 1.12 price screens below the kr 1.16 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Hofseth Biocare in your weekly email

Every Wednesday you see whether Hofseth Biocare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Hofseth BioCare ASA produces and sells health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, Turkey, rest of Europe, Japan, Asia, and the United States.

Show moreShow less

The company offers ProGo, a bioactive peptide for weight management and metabolic health; OmeGo, a fish oil that provides a full spectrum of fatty acids and omegas; CalGo and NT-II, which are calcium collagen complexes that support joint and bone health; CollaGo; and PetGo, a non-soluble protein.

Hofseth BioCare ASA was founded in 2000 and is headquartered in Ålesund, Norway.

Stock analysis

Hofseth Biocare ASA (HBC) currently trades at kr 1.12, while our estimate is kr 1.16, so the stock looks roughly fairly valued today (gap 3.8%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 0.8700 (bear) to kr 1.45 (bull), the price of kr 1.12 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Consumer Defensive sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Hofseth Biocare ASA reported revenue of 256M NOK in FY2025 versus 87.6M NOK in FY2021, a compound +30.8%/yr. Reported net income was −135M NOK in FY2025.

Key figures

Market cap 656M NOK (≈ $68.5M) Micro · P/S ratio 2.71 · EPS (TTM) kr −0.3400 · Net margin −56.4% · Return on equity −346% · Return on assets (EBIT) −29.6% (5-year average) · Operating margin −19.6% · Revenue (TTM) 242M NOK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 37% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Defensive peers we cover trades at 5% fair-value upside, at 4%, HBC screens richer than that median.

Fair Value

Bear kr 0.8700 Fair Value kr 1.16 Bull kr 1.45
Price kr 1.12 · Upside +4.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 22
How much profit the company makes from its sales and capital
Quality Growth 39
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 18
Debt, balance sheet and risk of trouble
Investment 89
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 21
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 67
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−0.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.9%
Start year 2020 (pandemic). Over 10 years: +16.6% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+62.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−132.9% (2020) → −43.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch HBC, get fair value alerts →

Compare Hofseth Biocare ASA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 661 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside +4.0% · Above median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −34.2% · Bottom 25%
Net margin (12 months) −56.4% · Bottom 25%
Operating margin (12 months) −19.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −4.0% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Packaged Foods median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 2.71× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)39 · sector 33
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 30
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 55

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Packaged Foods stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Wilmar International Limited F34 2.94 SGD 4.94 SGD +68% vs HBC
Inner Mongolia Yili Industrial Group 600887 ¥31.74 ¥41.84 +32% vs HBC
The Kraft Heinz Company KHC $24.48 $29.20 +19% vs HBC
Foshan Haitian Flavouring and Food Company 603288 ¥34.89 ¥38.07 +9% vs HBC
General Mills, Inc GIS $33.52 $35.30 +5% vs HBC
Danone S.A BN €69.80 €50.65 −27% vs HBC
Nestlé S.A NESN CHF 87.72 CHF 59.51 −32% vs HBC
Kerry Group KRZ €101.70 €60.33 −41% vs HBC
Nestlé India Limited NESTLEIND ₹1,263 ₹724.74 −43% vs HBC
Yihai Kerry Arawana Holdings 300999 ¥25.27 ¥12.21 −52% vs HBC

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Hofseth Biocare ASA: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Hofseth Biocare ASA Fair Value". https://www.fairvalue-calculator.com/stock/HBC

Frequently asked questions

Is Hofseth Biocare ASA (HBC) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is kr 1.16 versus a price of kr 1.12, about +4% upside (fairly valued).
What is the fair value of HBC?
Our estimate for Hofseth Biocare ASA is kr 1.16 (as of Nov 10, 2026), built from audited fundamentals. The current price: kr 1.12.
What is the quality score of HBC?
Hofseth Biocare ASA has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hofseth Biocare ASA (HBC)?
Our calculated price target is the estimate of kr 1.16 (as of Nov 10, 2026). Cautious scenario kr 0.8700, optimistic scenario kr 1.45. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Hofseth Biocare ASA stock forecast for 2026?
Our estimate puts fair value at kr 1.16, about +4% upside versus a price of kr 1.12 (fairly valued). Cautious scenario kr 0.8700, optimistic scenario kr 1.45. The calculation is refreshed regularly with new filings.
What is the revenue of Hofseth Biocare ASA (HBC)?
Hofseth Biocare ASA reported trailing-twelve-month revenue of about 242M NOK (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Hofseth Biocare ASA (HBC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hofseth Biocare ASA it is kr 1.16 per share (as of Nov 10, 2026), against a price of kr 1.12.
Is Hofseth Biocare ASA stock overvalued or undervalued in 2026?
As of Nov 10, 2026, HBC trades below its calculated fair value: price kr 1.12, fair value kr 1.16, a gap of about +4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HBC?
No. The price is what the market pays today (kr 1.12); the fair value is what the company's own numbers justify (kr 1.16). For Hofseth Biocare ASA the two are kr 0.0450 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hofseth Biocare ASA worth?
The market values Hofseth Biocare ASA at about 656M NOK (market capitalisation, as of Nov 10, 2026). Per share that is kr 1.12; our models calculate a fair value of kr 1.16 per share.
What do the bullish and bearish scenarios say about HBC?
Our models span a range for Hofseth Biocare ASA: cautious scenario kr 0.8700, base kr 1.16, optimistic kr 1.45 per share (as of Nov 10, 2026, price kr 1.12). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Hofseth Biocare ASA (HBC)?
Balance-sheet figures for Hofseth Biocare ASA (as of Nov 10, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is HBC from its 52-week high?
Hofseth Biocare ASA trades at kr 1.12, about 37% below its 52-week high of kr 1.76 and 3% above the low of kr 1.09 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of kr 1.16 is for.
Which stocks are comparable to Hofseth Biocare ASA?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hofseth Biocare ASA stock attractive at the current price?
The data as of Nov 10, 2026: price kr 1.12, calculated fair value kr 1.16 (+4%), Quality Score 32/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.3% above its aggregate fair value. Hofseth Biocare ASA currently trades 4% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hofseth Biocare ASA (HBC)?
The closing price on Nov 13, 2026 was kr 1.12. Our estimate is kr 1.16, about +4% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hofseth Biocare ASA right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Hofseth Biocare ASA

How large is the market capitalisation of Hofseth Biocare ASA (HBC)?
The market capitalisation of Hofseth Biocare ASA is 656M NOK (≈ $68.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hofseth Biocare ASA (HBC)?
The price-to-sales ratio of Hofseth Biocare ASA is 2.71 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hofseth Biocare ASA (HBC)?
Earnings per share at Hofseth Biocare ASA are kr −0.3400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Hofseth Biocare ASA (HBC)?
The net margin of Hofseth Biocare ASA is −56.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hofseth Biocare ASA (HBC)?
The return on equity (ROE) of Hofseth Biocare ASA is −346% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hofseth Biocare ASA (HBC)?
On an EBIT basis the return on assets of Hofseth Biocare ASA is −29.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hofseth Biocare ASA (HBC)?
The operating margin of Hofseth Biocare ASA is −19.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hofseth Biocare ASA (HBC)?
Revenue at Hofseth Biocare ASA is growing −4.0% versus a year earlier (3y avg +28.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Hofseth Biocare ASA (HBC) generate?
The free cash flow of Hofseth Biocare ASA is −41.7M NOK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Hofseth Biocare ASA (HBC) carry?
The net debt of Hofseth Biocare ASA is 191M NOK (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Hofseth Biocare ASA in the live analysis

One click puts Hofseth Biocare ASA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.